Endoscopy 2006; 38(8): 852
DOI: 10.1055/s-2006-925377
Letter to the Editor
© Georg Thieme Verlag KG Stuttgart · New York

Bowel preparation with oral sodium phosphate and renal disease

M.  Caswell1
  • 1 Product Safety & Evaluation, Fleet Laboratories, Lynchburg, Virginia, USA
Further Information

Publication History

Submitted 30 January 2006

Accepted after revision 22 February 2006

Publication Date:
28 August 2006 (online)

Mishra et al. [1] described two cases of severe hyperphosphatemia following ingestion of Fleet Phospho-Soda. One of the affected patients was a 51-year-old woman with end-stage renal disease, and the other was a 57-year-old man with chronic renal insufficiency. The authors failed to note that current professional Fleet Phospho-Soda labeling includes the warning, ”Do not use in patients with clinically significant impairment of renal function“ [2].

Fleet Laboratories is concerned that Fleet Phospho-Soda should be used only in patients who do not have contraindications to the drug product.

Competing Interests: Dr Caswell is employed by Fleet Laboratories, manufacturers of Fleet Phospho-soda.

References

  • 1 Mishra R, Kaufman D, Mattern III J, Dutta S K. Severe hyperphosphatemia and hypocalcemia caused by bowel preparation for colonoscopy using oral sodium phosphate in end-stage renal disease.  Endoscopy. 2005;  37 1259-1260
  • 2 Murray L, senior editor. Physicians’ Desk Reference, 60th ed.  Montvale, NJ; Thompson Healthcare, Inc. 2006: 1170-1172

M. Caswell, Ph. D.

Director of Product Safety & EvaluationFleet Laboratories

4615 Murray PlaceLynchburg, VA 24502USA

Fax: +1-434-528-0430

Email: caswellm@cbfleet.com